LOS ANGELES--(BUSINESS WIRE)--CytRx Corporation (Nasdaq: CYTR), a biopharmaceutical company engaged in the development and commercialization of human therapeutics, today announced that Bin Zhang, Ph.D., Associate Director of Biochemistry and Screening, is invited to present CytRx’s novel high-content screening (HCS) assay for small molecule amplifiers of the cellular chaperone response at GTCbio’s Third Assay Development & Screening Technologies Conference being held June 5 and 6 in San Francisco. Some of the hit compounds from the HCS assay showed significant cellular protection under various stress conditions including cell-based models for both stroke and Parkinson’s disease.
